NEW YORK (GenomeWeb News) – Italian firm A. Menarini Diagnostics will exclusively distribute Transgenomic's Surveyor Scan and Wave Micro-capillary electrophoresis (MCE) mutation detection system throughout Europe as part of a deal announced today.
Under the terms of the deal, Menarini, based in Florence, Italy, will make the Transgenomic technology available to the more than 2,000 pathologists in its European network. Financial details were not disclosed.
The Surveyor technology uses "PCR amplification reaction and hybridization to form mispaired DNA molecules where there are mutations," Transgenomic said in a statement. It added that the Surveyor Scan KRAS kit has performed equivalently to allele-specific methods, such as Scorpion amplification refractory mutation system and pyrosequencing.
During the past two years, Transgenomic has marketed the kits for cancer genes such as KRAS, BRAF, and PI-3 kinase for its Wave systems. Earlier this year, the firm began developing the technology for Wave MCE technology, and today's agreement "will accelerate the adoption of our Surveyor Scan Mutation Detection kits and Wave MCE platform among this key" market of pathologists, Transgenomic CEO Craig Tuttle said.